Background of the event
In the past two years, we naively thought that vaccines would be the end of the COVID-19 epidemic.
Recently, the recurrence of epidemics has made us fully understand that vaccines are not only not the end of the epidemic, but also put those who have not been vaccinated to bear greater risks.
This is because once a vaccinated person is infected, it is likely that he or she will have asymptomatic or mild symptoms. The lack of obvious symptoms may easily cause the person to ignore it, which may lead to the infection being undetected for a long time.
This creates opportunities for the virus to spread, and those who have not been vaccinated may still develop severe illness if infected.
This is also the main reason why the new coronavirus has broken out at multiple points recently and has been hidden for a long time.
Therefore, vaccines cannot build the Great Wall of Immunity. The terminator of the virus is still the specific drug that is being intensively developed around the world.
R&D process
Recently, the new coronavirus monoclonal neutralizing antibody ambavir was developed by Zhang Linqi, a tenured professor at Tsinghua University School of Medicine and director of the Tsinghua University Global Health and Infectious Disease Research Center. The monoclonal antibody/romisevirumab combination therapy has received emergency approval from the my country National Medical Products Administration for the treatment of adults and adolescents with new coronavirus infection who have mild, common and high-risk factors for progression to severe coronavirus. The first novel coronavirus neutralizing antibody combination treatment drug with independent intellectual property rights approved for marketing.
It is reported that there are currently 6 specific COVID-19 drugs independently developed in my country, and many of them have entered Phase III clinical trials.
The COVID-19-specific immunoglobulin developed by China Sinopharm has been approved for clinical trials as a therapeutic drug; the neutralizing antibody DXP604, jointly developed by Peking University’s Xie Xiaoliang team and Danxu Biotech, has been approved as a “compassionate use drug” "It is used in Ditan Hospital in Beijing; the oral drug Azivudine is currently undergoing Phase III clinical trials in China, Russia and other places; the new generation androgen receptor antagonist Proxalutamide has received emergency use authorization from Paraguay.
Listed company of COVID-19 specific drugs
Tuoxin Pharmaceutical: The company provides EIDD-2801, the raw material of which is uridine. EIDD-2801 is the raw material for the production of Molnupiravir, the oral drug for COVID-19.
Sutaishen: The company’s Phase I clinical trial (domestic) of STSA-1002 injection completed the administration of the first subject. STSA-1002 injection can treat severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by the virus (SARS-CoV-2). As the company's key research and development project, BDB-001 drug is currently promoting the implementation of phase II/III clinical trials for severe COVID-19 globally.
Hanyu Pharmaceutical: The company and the Institute of Microbiology, Chinese Academy of Sciences plan to cooperate to develop peptide nasal spray drugs for the prevention and treatment of COVID-19. At the same time, the company also belongs to the recently popular Helicobacter pylori concept stocks.
Guangshengtang: The company signed a "Cooperation Development Contract" with WuXi AppTec on the research and development project of a new class of 3-CL (3C-like) protease inhibitor for the treatment of new coronavirus infection.
Frontier Biotech: The company’s new injectable anti-COVID-19 drug FB2001 has launched Phase I clinical trials in the United States and has been approved to conduct Phase I clinical bridging trials in China.
Junshi Biological: The company has VV116, the only domestic small molecule drug for the treatment of COVID-19 that has been approved for clinical trials. After passing clinical trials within the year, the company will initiate marketing applications as soon as possible.
This article does not constitute investment advice.